Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789047 · ClinicalTrials.gov registry record · Phase 2
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
A Phase 2 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01789047 is a Phase 2 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT01789047, a Phase 2 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD) patients who continue to have dyskinesia on amantadine.
Interventions
- DRUG Placebo
- DRUG Amantadine
- DRUG Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789047
The ClinicalTrials.gov registry entry for NCT01789047 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01789047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789047 about?
NCT01789047 is a clinical study titled "Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease". The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD) patients who continue to have dyskinesia on amantadine.
What is the current status of trial NCT01789047?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01789047?
The interventions under investigation include: Placebo (DRUG), Amantadine (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT01789047?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.